Navigation Links
Experimental drug may extend therapeutic window for stroke
Date:7/17/2012

company's 3K3A-APC is a genetically engineered variant of the naturally occurring activated protein C (APC), which plays a role in the regulation of blood clotting and inflammation. APC has cell-protecting, anti-inflammatory and anti-coagulant properties; 3K3A-APC has reduced anti-coagulant ability, which minimizes the risk of bleeding induced by normal APC. The protective effect of 3K3A-APC on the lining of blood vessels in the brain further helps prevent bleeding caused by tPA.

In collaboration with the University of Rochester Medical Center, Henry Ford Health Sciences Center, University of Arizona College of Medicine and The Scripps Research Institute, Zlokovic and his team gave tPA alone and in combination with 3K3A-APC to mice and rats four hours after stroke. They also gave 3K3A-APC for three consecutive days after stroke. They measured the amount of brain damage, bleeding and motor ability of the rodents up to seven days afterward.

The researchers found that, under those conditions, tPA therapy alone caused bleeding in the brain and did not reduce brain damage or improve motor ability when compared to the control. The combination of tPA and 3K3A-APC, however, reduced brain damage by more than half, eliminated tPA-induced bleeding and significantly improved motor ability.

"Dr. Zlokovic's study really demonstrates the promise of the drug and we are eager to show the same results in human clinical trials," said Kent Pryor, Ph.D., M.B.A., ZZ Biotech's chief operating officer.

Previous research suggests that the experimental drug may also protect against other neurological maladies such as amyotrophic lateral sclerosis and traumatic brain injury as a standalone therapy.

"We are encouraged by these results," said Joe Romano, CEO and president of ZZ Biotech. "In terms of improving treatment for stroke and other neurological diseases, this could be really exciting."


'/>"/>

Contact: Alison Trinidad
alison.trinidad@usc.edu
323-442-3941
University of Southern California - Health Sciences
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Experimental Gel May Help Those With Advanced Parkinsons
4. Experimental Drug Eases Autistic Behaviors in Mice
5. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
6. Experimental drug improves muscle strength among male cancer patients
7. Experimental Vaccine Seems to Stop Nicotine Addiction in Mice
8. Content Writing King Announces Cancellation Of Experimental Video Creation Process For Their Article Marketing Website
9. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
10. Healthy Behaviors Extend Life After Cancer, Experts Say
11. Exercise and a healthy diet of fruits and vegetables extends life expectancy in women in their 70s
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Sugar Land, TX (PRWEB) July 30, 2014 ... pharmacy recently announced their plans to move to a new ... been announced, but they will be moving soon. , MedX ... 6302 W Broadway in Pearland, TX 77581. This is the ... than their current one and will include a drive thru ...
(Date:7/30/2014)... 2014 Ticket Down is a ... vs. Chivas Guadalajara friendly exhibition match at the Red ... the one team that was left standing as the best ... through the world’s largest football competition and even embarrassed the ... to the cup. Germany was led by seven players that ...
(Date:7/30/2014)... 30, 2014 Conducting Advanced Root ... Thinking Skills and Innovative Techniques to Improve the ... and FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... #1 reason for 483 observations since 1997. , ... a successful CAPA program has never been more ...
(Date:7/30/2014)... in sub-Saharan Africa is being revitalized and expanded ... enrollment, broadening curricula, upgrading Internet access and providing ... In the first substantial publication by participants of ... more than 225 authors detailed progress being made ... a supplement being published today by the journal ...
(Date:7/30/2014)... artemisinin, the main drug to treat malaria, is ... Plasmodium falciparum ( P. falciparum ) parasites ... by a genetic mutation in the parasites. However, ... to a standard three-day coursehas proved highly effective ... published today in the New England Journal ...
Breaking Medicine News(10 mins):Health News:MedX Pharmacy Relocates to New Facility 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2
... -- Teenage girls who develop post-traumatic stress disorder after being ... research shows. In the study, researchers analyzed data collected ... part in a national telephone survey and were interviewed up ... time, 270 of the girls (15 percent) reported sexual victimization. ...
... Chicago College of Medicine have been awarded more than $11.7 ... The study, part of a multi-pronged investigation into acute ... Lung and Blood Institute, one of the National Institutes of ... acute respiratory distress syndrome, result from pulmonary edema -- leaky ...
... , FRIDAY, July 29 (HealthDay News) -- An ... -- a specific breed of dog known for truffle hunting, ... newly identified gene has enabled the development of a DNA ... for humans, providing new perspective on the development of a ...
... is available in Spanish . Patients suffering ... attacked and pursued, with the particularity that they express them ... Neurology has published the third consecutive work in five ... The first work showed in 2006 that 45% ...
... ethnic groups are more likely than others to store dangerous fat ... new study. This organ-hugging fat, which can lead to ... South Asia, the Canadian researchers reported in the July 28 online ... study showed South Asians have less space to store fat below ...
... bikers, brains, may also be contributing to hearing loss. ... out why. The distinctive roar of a Harley,s ... source of noise for motorcyclists is actually generated by ... speeds, the sound can exceed safe levels. Now, scientists ...
Cached Medicine News:Health News:Sexual Assault Doesn't Cause Binge Drinking in Girls: Study 2Health News:$12 million NIH grant to study acute lung injury 2Health News:New Dog Gene May Shed Light on Childhood Epilepsy 2Health News:REM sleep behavior disorder is a risk factor for Parkinson's disease 2Health News:Some Ethnic Groups More Vulnerable to Dangerous Fat 2
(Date:7/30/2014)... 2014 Cynosure, Inc. (NASDAQ: ... for non-invasive and minimally invasive applications, today announced that the ... Officer and Chief Financial Officer Timothy W. Baker ... 53, will continue to serve as CFO and will take ... remains Chairman and Chief Executive Officer. "Tim ...
(Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... , SALT LAKE CITY, Dec. 16 ... "Company"), a medical device company engaged in the development and ... that Joe Pepper, PhD, has been appointed to the TechniScan ... "Joe has extensive experience running small to large medical devices ...
... EVANSTON, Ill., Dec. 16 Naurex Inc., a new clinical ... disorders based on its novel GFPA NMDA receptor modulators, today ... of its lead compound GLYX-13 and has successfully dosed the ... functional partial agonist (GFPA) selective modulator of the NMDA receptor, ...
Cached Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3
... K-ASSAY ASO / RF / ... to be used as a ... concentration for monitoring the performance ... Rheumatoid Factor (RF), and C-Reactive ...
... of benchtop microcentrifuges with the 5424. ... aerosol-tight rotor and a unique, contoured ... ,Model 5424 expands its application range ... microcentrifuge tubes, miniprep spin columns and ...
... hand, the Jarvik 2000 pump is about the ... titanium shell sits a direct-current motor, a rotor ... moving part: a small, spinning titanium impeller that ... 7 liters per minute. Rather than take over ...
... VentrAssist is a new third generation cardiac assist ... heart transplants for patients suffering heart failure., ,It ... left ventricle of the diseased heart to help ... restoring a better quality of life. , ,It ...
Medicine Products: